Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas
about
Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signalingColorectal cancer chemoprevention: is this the future of colorectal cancer prevention?Chemoprevention in familial adenomatous polyposisRegulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinicCardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionThe PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient miceCurrent concepts in colorectal cancer preventionMeat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California Teachers Study.Primary prevention of colorectal cancer.Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancerAspirin and familial adenomatous polyposis: coming full circlePerspective: Chemoprevention of colorectal neoplasia: Translating scientific promise into clinical practiceDFMO: targeted risk reduction therapy for colorectal neoplasia.Cellular diamine levels in cancer chemoprevention: modulation by ibuprofen and membrane plasmalogens.Progress against cancer (1971-2011): how far have we come?Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography.Meat consumption, ornithine decarboxylase gene polymorphism, and outcomes after colorectal cancer diagnosis.Knockdown of antizyme inhibitor decreases prostate tumor growth in vivoTargeting polyamines and inflammation for cancer preventionRecent advances in the development of polyamine analogues as antitumor agents.Rapidly cycling Lgr5+ stem cells are exquisitely sensitive to extrinsic dietary factors that modulate colon cancer risk.Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.Cancer chemoprevention locks onto a new polyamine metabolic target.Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use.Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling.Regulation of Polyamine Metabolism by Curcumin for Cancer Prevention and Therapy.Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model.Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.Metformin and Colorectal Cancer
P2860
Q21245755-B1551058-F2FD-43DB-8FCA-09D11BA16407Q24620457-14BF2CC9-FA17-4746-A14F-C1BD6D5448F5Q27023845-D8403282-808B-478E-A096-5ED502B7D90FQ30498812-7383749C-67D1-4DA3-9722-2151704BD6C4Q33574045-9FA35504-332E-42CD-BCA8-3FE35913EF7DQ33874466-F7DF1A64-31F9-4BBB-98F3-46B023C6DA21Q34065803-17A0C09D-56B0-42E5-BBB8-BA7C946FBC02Q34097339-0F3705AB-49D3-4442-AF00-ADB9C3B6DD9CQ34165145-59A88C7A-DFB1-463B-A934-8D60F3F296C9Q34176387-A5E414EB-0052-4515-A225-0F96AA819751Q34296467-937D0B55-3931-4DAE-81B0-7D3F93F7AB11Q34992425-6C91187E-E86E-456E-914A-C7594E162210Q35064951-9A974CFE-729D-4124-B94E-583060155B49Q35583635-66F6F50F-F96D-42F3-A24D-D0115A37351DQ35595617-B4A5FA41-A775-46F7-BED3-51C2F3AE778EQ35722470-C703F40C-A296-43CF-BDEC-A6A29CF520B0Q36036531-8C090B09-9AB4-405C-B42A-75675689128BQ36450416-7F708E21-8A40-4B31-9D3C-71C06BB6FFF7Q36638469-78AABF93-6C3C-4130-BE7F-680DF5879041Q36653461-CCEAAD9B-AFF9-418E-BF3E-21E17FFE4D61Q37522449-EABD5367-2C8A-45B9-B2AA-EFCC1D272D38Q37603293-F26E6564-25C6-404A-A892-AB39233AB18CQ37679988-594AD410-284A-42BE-8381-FD293AF325EBQ37681944-1E06C8D1-7C3E-4DB8-AC17-1901A8EE7FB9Q37725987-525DCB96-281B-4B85-AAB2-4989ADDBC1B5Q38738879-D1BFAF8B-063A-4E36-9444-5E955C760244Q47181119-163CA8CB-1049-4701-82C6-1A8DB36F7232Q48021881-B6DA84FE-9264-46A3-A4DC-B847E33727BAQ48506495-2AA9BC5D-35D8-4117-AD98-BC71158B1FD2Q58572220-F02AF5B1-9D46-4133-8340-01BCCF738CF4
P2860
Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@ast
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@en
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@nl
type
label
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@ast
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@en
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@nl
prefLabel
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@ast
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@en
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@nl
P2093
P2860
P1476
Risk of cardiovascular events ...... f sporadic colorectal adenomas
@en
P2093
Christine E McLaren
Daniel Pelot
Eugene W Gerner
Frank L Meyskens
Jason A Zell
Wen-Pin Chen
P2860
P304
P356
10.1158/1940-6207.CAPR-08-0203
P577
2009-03-03T00:00:00Z